Brady J. Gaynor
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Brady J. Gaynor has a total of 285 co-authors. Here are the top co-authors by number of shared publications:
- Braxton D. Mitchell
Department of Medicine, University of Maryland School of Medicine, Baltimore, MD
9 shared publications - John Walden Cole
Department of Neurology, University of Maryland School of Medicine, Baltimore, MD, USA
6 shared publications - Huichun Xu
Department of Medicine, University of Maryland School of Medicine, Baltimore (H.X.).
5 shared publications Patrick F. McArdle
Department of Medicine, School of Medicine, University of Maryland Baltimore
5 shared publicationsSteven J. Kittner
Department of Neurology Medicine, University of Maryland School of Medicine
5 shared publications- Bradford Burke Worrall
Departments of Neurology and Public Health Sciences, University of Virginia, Charlottesville
3 shared publications
Latest Publications
- 6 October 2026
- Published by Wolters Kluwer Health in Circulation
- Vol. 154 (14) , 1309-1321
Pathology of Genetic Variants in Spontaneous Coronary Artery Dissection
BACKGROUND: Spontaneous coronary artery dissection (SCAD) is characterized by a separation of the coronary artery wall, causing myocardial infarction and sudden death. This study is one of the first to clarify the impact of pathological genetic variants in candidate SCAD-related genes on the histopathological and morphological properties of human SCAD lesions. METHODS: A total of 28 SCAD cases were selected from the CVPath Autopsy Registry. Histological differences in collagen and smooth muscle cells were compared among 3 groups: culprit SCAD (C-SCAD), defined as the coronary segment containing a dissection in cases with SCAD; nonculprit SCAD, defined as unaffected coronary segments (ie, healthy arteries) in cases with SCAD; and non-SCAD controls. Whole-exome sequencing was performed, and the identified variants were filtered to isolate pathogenic or likely pathogenic variants. Protein expression corresponding to the identified variants was assessed by immunostaining. RESULTS: Collagen content was significantly reduced in C-SCAD lesions compared with controls, and immunohistochemical staining for smoothelin was reduced in the media of C-SCAD lesions compared with controls, whereas there were no significant differences between C-SCAD and nonculprit SCAD. Further, the nuclear height/width ratio of smooth muscle cells was increased, suggesting smooth muscle cell phenotypic modulation. In whole-exome sequencing analysis, pathogenic or likely pathogenic variants were detected in 25% of cases, which showed a higher frequency of multivessel dissection. In SCAD cases with pathogenic or likely pathogenic variants in COL3A1 (collagen type III alpha 1), FBN1 (fibrillin-1), or FLNA (filamin A), the expression of the corresponding protein was reduced in the media. CONCLUSIONS: Reduced medial collagen and smooth muscle cell phenotypic modulation may be possible predisposing conditions for SCAD, regardless of the presence of pathogenic or likely pathogenic variants. The presence of pathogenic variants in extracellular matrix–related genes may further compromise arterial wall medial integrity, contributing to more severe disease. These findings provide novel pathological and genetic insights into the pathogenesis of SCAD and may inform future diagnostic and therapeutic strategies.
- 6 October 2026
- Published by Wolters Kluwer Health in Circulation
- Vol. 154 (14) , 1309-1321
Pathology of Genetic Variants in Spontaneous Coronary Artery Dissection
BACKGROUND: Spontaneous coronary artery dissection (SCAD) is characterized by a separation of the coronary artery wall, causing myocardial infarction and sudden death. This study is one of the first to clarify the impact of pathological genetic variants in candidate SCAD-related genes on the histopathological and morphological properties of human SCAD lesions. METHODS: A total of 28 SCAD cases were selected from the CVPath Autopsy Registry. Histological differences in collagen and smooth muscle cells were compared among 3 groups: culprit SCAD (C-SCAD), defined as the coronary segment containing a dissection in cases with SCAD; nonculprit SCAD, defined as unaffected coronary segments (ie, healthy arteries) in cases with SCAD; and non-SCAD controls. Whole-exome sequencing was performed, and the identified variants were filtered to isolate pathogenic or likely pathogenic variants. Protein expression corresponding to the identified variants was assessed by immunostaining. RESULTS: Collagen content was significantly reduced in C-SCAD lesions compared with controls, and immunohistochemical staining for smoothelin was reduced in the media of C-SCAD lesions compared with controls, whereas there were no significant differences between C-SCAD and nonculprit SCAD. Further, the nuclear height/width ratio of smooth muscle cells was increased, suggesting smooth muscle cell phenotypic modulation. In whole-exome sequencing analysis, pathogenic or likely pathogenic variants were detected in 25% of cases, which showed a higher frequency of multivessel dissection. In SCAD cases with pathogenic or likely pathogenic variants in COL3A1 (collagen type III alpha 1), FBN1 (fibrillin-1), or FLNA (filamin A), the expression of the corresponding protein was reduced in the media. CONCLUSIONS: Reduced medial collagen and smooth muscle cell phenotypic modulation may be possible predisposing conditions for SCAD, regardless of the presence of pathogenic or likely pathogenic variants. The presence of pathogenic variants in extracellular matrix–related genes may further compromise arterial wall medial integrity, contributing to more severe disease. These findings provide novel pathological and genetic insights into the pathogenesis of SCAD and may inform future diagnostic and therapeutic strategies.
- Open Access
Identification of Plasma Protein Biomarkers for Early-Onset Stroke through Mendelian Randomization
Background: Stroke incidence is declining in older adults but rising in younger populations. Circulating plasma proteins are promising biomarkers of vascular disease, yet their causal role in early-onset stroke (EOS) remains unclear. We used proteome-wide Mendelian randomization (MR) to identify proteins causally associated with EOS and its subtypes. Methods: We conducted two-sample MR using protein quantitative trait loci from 54,219 UK Biobank participants and summary-level association results from up to 11,114 EOS cases (onset −5 ) were clumped for linkage disequilibrium and used as instrumental variables. Causal effects were estimated using inverse-variance weighted MR, with sensitivity analyses to assess robustness. Stroke subtypes were defined using TOAST criteria. Results: Among 1,041 proteins tested, 11 were significantly associated with EOS after multiple testing correction. Genetically predicted higher levels of proteins encoded by ABO, F11, F7, MLN, BTD, MEP1B, and VAMP8 increased EOS risk (ORs ~1.05-1.32 per SD), whereas higher levels of proteins encoded by FN1, GRK5, EHBP1, and FCN2 were protective. Eight additional proteins showed subtype-specific associations. Key signals converged on coagulation and thromboinflammatory pathways, particularly ABO, F11, and F7, with consistent evidence across analyses. Cross-trait analyses demonstrated overlap with late-onset stroke, venous thromboembolism, and cardiometabolic risk factors, supporting shared biological mechanisms. Drug-target mapping highlighted Factor XI as a leading therapeutic target, supported by existing inhibitors (e.g., abelacimab, milvexian). Conclusions: This large-scale proteome-wide MR study identified multiple plasma proteins with likely causal roles in EOS, implicating coagulation, platelet activation, extracellular matrix remodeling, and immune pathways in disease etiology. These findings highlight biologically plausible biomarkers and prioritize druggable targets, particularly Factor XI, for prevention of EOS and demonstrate the value of proteogenomic approaches for uncovering disease mechanisms and informing precision prevention strategies.
Open AccessIdentification of Plasma Protein Biomarkers for Early-Onset Stroke through Mendelian Randomization
Background: Stroke incidence is declining in older adults but rising in younger populations. Circulating plasma proteins are promising biomarkers of vascular disease, yet their causal role in early-onset stroke (EOS) remains unclear. We used proteome-wide Mendelian randomization (MR) to identify proteins causally associated with EOS and its subtypes. Methods: We conducted two-sample MR using protein quantitative trait loci from 54,219 UK Biobank participants and summary-level association results from up to 11,114 EOS cases (onset −5 ) were clumped for linkage disequilibrium and used as instrumental variables. Causal effects were estimated using inverse-variance weighted MR, with sensitivity analyses to assess robustness. Stroke subtypes were defined using TOAST criteria. Results: Among 1,041 proteins tested, 11 were significantly associated with EOS after multiple testing correction. Genetically predicted higher levels of proteins encoded by ABO, F11, F7, MLN, BTD, MEP1B, and VAMP8 increased EOS risk (ORs ~1.05-1.32 per SD), whereas higher levels of proteins encoded by FN1, GRK5, EHBP1, and FCN2 were protective. Eight additional proteins showed subtype-specific associations. Key signals converged on coagulation and thromboinflammatory pathways, particularly ABO, F11, and F7, with consistent evidence across analyses. Cross-trait analyses demonstrated overlap with late-onset stroke, venous thromboembolism, and cardiometabolic risk factors, supporting shared biological mechanisms. Drug-target mapping highlighted Factor XI as a leading therapeutic target, supported by existing inhibitors (e.g., abelacimab, milvexian). Conclusions: This large-scale proteome-wide MR study identified multiple plasma proteins with likely causal roles in EOS, implicating coagulation, platelet activation, extracellular matrix remodeling, and immune pathways in disease etiology. These findings highlight biologically plausible biomarkers and prioritize druggable targets, particularly Factor XI, for prevention of EOS and demonstrate the value of proteogenomic approaches for uncovering disease mechanisms and informing precision prevention strategies.
- 1 February 2026
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 46 (2)
Lipid-Related Polygenic Risk Score and Its Association With Plaque Rupture Versus Erosion
BACKGROUND: Distinct plaque morphologies underlie the major causes of acute coronary syndrome and sudden cardiac death. We used polygenic risk scores (PRSs) for hypercholesterolemia and hypertriglyceridemia, 2 major risk factors for coronary artery disease (CAD), to evaluate the relative contributions of these risk factors to specific plaque morphologies, specifically plaque rupture and erosion. METHODS: DNA was extracted from formalin-fixed paraffin-embedded tissues and genotyped for 954 subjects from our sudden death autopsy registry, with cause of death determined by autopsy. LDL (low-density lipoprotein)–specific and triglyceride-specific PRSs were constructed based on the Global Lipids Genetics Consortium genome-wide association study results, excluding variants associated with both traits ( P P =0.017), ≥75% lumen narrowing (OR, 1.33 [95% CI, 1.13–1.57]; P P =0.016), and CAD-related death (OR, 1.31 [95% CI, 1.13–1.52]; P P =0.020) and showed a trend toward association with plaque rupture (OR, 1.15 [95% CI, 0.98–1.35]; P =0.091). No association was observed between LDL-/triglyceride-specific PRS and plaque erosion. CONCLUSIONS: This is the first study to associate lipid PRSs with specific plaque morphologies, revealing distinct pathogenic mechanisms underlying plaque rupture and erosion. Early genetic risk stratification and subsequent lipid-lowering interventions may provide substantial clinical benefits in mitigating cardiovascular risk, particularly in relation to plaque rupture. Our findings raise questions about the effectiveness of such strategies in preventing plaque erosion, suggesting the need for further investigation into its underlying pathogenesis.
- 1 February 2026
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 46 (2)
Lipid-Related Polygenic Risk Score and Its Association With Plaque Rupture Versus Erosion
BACKGROUND: Distinct plaque morphologies underlie the major causes of acute coronary syndrome and sudden cardiac death. We used polygenic risk scores (PRSs) for hypercholesterolemia and hypertriglyceridemia, 2 major risk factors for coronary artery disease (CAD), to evaluate the relative contributions of these risk factors to specific plaque morphologies, specifically plaque rupture and erosion. METHODS: DNA was extracted from formalin-fixed paraffin-embedded tissues and genotyped for 954 subjects from our sudden death autopsy registry, with cause of death determined by autopsy. LDL (low-density lipoprotein)–specific and triglyceride-specific PRSs were constructed based on the Global Lipids Genetics Consortium genome-wide association study results, excluding variants associated with both traits ( P P =0.017), ≥75% lumen narrowing (OR, 1.33 [95% CI, 1.13–1.57]; P P =0.016), and CAD-related death (OR, 1.31 [95% CI, 1.13–1.52]; P P =0.020) and showed a trend toward association with plaque rupture (OR, 1.15 [95% CI, 0.98–1.35]; P =0.091). No association was observed between LDL-/triglyceride-specific PRS and plaque erosion. CONCLUSIONS: This is the first study to associate lipid PRSs with specific plaque morphologies, revealing distinct pathogenic mechanisms underlying plaque rupture and erosion. Early genetic risk stratification and subsequent lipid-lowering interventions may provide substantial clinical benefits in mitigating cardiovascular risk, particularly in relation to plaque rupture. Our findings raise questions about the effectiveness of such strategies in preventing plaque erosion, suggesting the need for further investigation into its underlying pathogenesis.
- 1 March 2025
- Published by Wolters Kluwer Health in Stroke
- Vol. 56 (3) , 640-648
Impact of Conventional Stroke Risk Factors on Early- and Late-Onset Ischemic Stroke: A Mendelian Randomization Study
BACKGROUND: Stroke incidence is decreasing in older ages but increasing in young adults. These divergent trends are at least partially attributable not only to diverging trends in stroke risk factors but may also be due to differences in the impact of stroke risk factors at different ages. To address this latter possibility, we used Mendelian randomization to assess differences in the association of stroke risk factors between early-onset ischemic stroke ([EOS]; onset 18–59 years) and late-onset ischemic stroke ([LOS]; onset ≥60 years). METHODS: We identified genetic variants from the GWAS Catalog for use as instrumental variables to proxy conventional stroke risk factors and then estimated the effects of these variants on risk factors in younger and older individuals in the UK Biobank. We then used these estimates to estimate the causal effects of stroke risk factors on EOS (n=6728 cases) and LOS (n=9272) cases from SiGN (Stroke Genetic Network) and the EOSC (Early-Onset Stroke Consortium). Lastly, we compared odds ratios between EOS and LOS, stratified by TOAST (Trial of ORG 10172 in Acute Stroke Treatment) subtypes, to determine if differences between estimates could be attributed to differences in stroke subtype distributions. RESULTS: EOS was associated with higher levels of body mass index, blood pressure, type 2 diabetes, and lower levels of HDL (high-density lipoprotein) cholesterol (all P ≤0.002), whereas LOS was associated with higher levels of systolic blood pressure ( P =0.0001). The causal effect of body mass index on stroke was significantly stronger for EOS than for LOS (odds ratio, 1.26 versus 1.03; P =0.008). After the subtype-stratified analysis, the difference in causal effect sizes between EOS and LOS for body mass index diminished and was no longer significant. CONCLUSIONS: These results support a causal relationship between body mass index, blood pressure, type 2 diabetes, and HDL cholesterol levels with EOS and blood pressure levels in LOS. Interventions that target these traits may reduce stroke risk.
- 1 March 2025
- Published by Wolters Kluwer Health in Stroke
- Vol. 56 (3) , 640-648
Impact of Conventional Stroke Risk Factors on Early- and Late-Onset Ischemic Stroke: A Mendelian Randomization Study
BACKGROUND: Stroke incidence is decreasing in older ages but increasing in young adults. These divergent trends are at least partially attributable not only to diverging trends in stroke risk factors but may also be due to differences in the impact of stroke risk factors at different ages. To address this latter possibility, we used Mendelian randomization to assess differences in the association of stroke risk factors between early-onset ischemic stroke ([EOS]; onset 18–59 years) and late-onset ischemic stroke ([LOS]; onset ≥60 years). METHODS: We identified genetic variants from the GWAS Catalog for use as instrumental variables to proxy conventional stroke risk factors and then estimated the effects of these variants on risk factors in younger and older individuals in the UK Biobank. We then used these estimates to estimate the causal effects of stroke risk factors on EOS (n=6728 cases) and LOS (n=9272) cases from SiGN (Stroke Genetic Network) and the EOSC (Early-Onset Stroke Consortium). Lastly, we compared odds ratios between EOS and LOS, stratified by TOAST (Trial of ORG 10172 in Acute Stroke Treatment) subtypes, to determine if differences between estimates could be attributed to differences in stroke subtype distributions. RESULTS: EOS was associated with higher levels of body mass index, blood pressure, type 2 diabetes, and lower levels of HDL (high-density lipoprotein) cholesterol (all P ≤0.002), whereas LOS was associated with higher levels of systolic blood pressure ( P =0.0001). The causal effect of body mass index on stroke was significantly stronger for EOS than for LOS (odds ratio, 1.26 versus 1.03; P =0.008). After the subtype-stratified analysis, the difference in causal effect sizes between EOS and LOS for body mass index diminished and was no longer significant. CONCLUSIONS: These results support a causal relationship between body mass index, blood pressure, type 2 diabetes, and HDL cholesterol levels with EOS and blood pressure levels in LOS. Interventions that target these traits may reduce stroke risk.
- Open Access
The Impact of Conventional Stroke Risk Factors on Early and Late Onset Ischemic Stroke: a Mendelian Randomization Study
Objective Although stroke incidence is decreasing in older ages, it is increasing in young adults. While these divergent trends in stroke incidence are at least partially attributable to diverging prevalence trends in stoke risk factors, age-dependent differences in the impact of stroke risk factors on stroke may also contribute. To address this issue, we utilized Mendelian Randomization (MR) to assess differences in the association of stroke risk factors between early onset ischemic stroke (EOS) and late onset ischemic stroke (LOS). Methods We employed a two-sample MR design with inverse variance weighting as the primary method of analysis. Using large publicly available genome-wide association summary results, we calculated MR estimates for conventional stroke risk factors (body mass index, total, HDL-and LDL-cholesterol, triglycerides, type 2 diabetes, systolic and diastolic blood pressure, and smoking) in EOS cases (onset 18-59 years, n = 6,728) and controls from the Early Onset Stroke Consortium and in LOS cases (onset ≥ 60 years, n = 9,272) and controls from the Stroke Genetics Network. We then compared odds ratios between EOS and LOS, stratified by TOAST subtypes, to determine if any differences observed between effect sizes could be attributed to differences in the distribution of stroke subtypes. Results EOS was significantly associated with all risk factors except for total cholesterol levels, and LOS was associated with all risk factors except for triglyceride and total cholesterol levels. The associations of BMI, DBP, SBP, and HDL-cholesterol were significantly stronger in EOS than LOS (all p < 0.004). The differential distribution of stroke subtypes could not explain the difference in effect size observed between EOS and LOS. Conclusion These results suggest that interventions targeted at lowering body mass index and blood pressure may be particularly important for reducing stroke risk in young adults.
Open AccessThe Impact of Conventional Stroke Risk Factors on Early and Late Onset Ischemic Stroke: a Mendelian Randomization Study
Objective Although stroke incidence is decreasing in older ages, it is increasing in young adults. While these divergent trends in stroke incidence are at least partially attributable to diverging prevalence trends in stoke risk factors, age-dependent differences in the impact of stroke risk factors on stroke may also contribute. To address this issue, we utilized Mendelian Randomization (MR) to assess differences in the association of stroke risk factors between early onset ischemic stroke (EOS) and late onset ischemic stroke (LOS). Methods We employed a two-sample MR design with inverse variance weighting as the primary method of analysis. Using large publicly available genome-wide association summary results, we calculated MR estimates for conventional stroke risk factors (body mass index, total, HDL-and LDL-cholesterol, triglycerides, type 2 diabetes, systolic and diastolic blood pressure, and smoking) in EOS cases (onset 18-59 years, n = 6,728) and controls from the Early Onset Stroke Consortium and in LOS cases (onset ≥ 60 years, n = 9,272) and controls from the Stroke Genetics Network. We then compared odds ratios between EOS and LOS, stratified by TOAST subtypes, to determine if any differences observed between effect sizes could be attributed to differences in the distribution of stroke subtypes. Results EOS was significantly associated with all risk factors except for total cholesterol levels, and LOS was associated with all risk factors except for triglyceride and total cholesterol levels. The associations of BMI, DBP, SBP, and HDL-cholesterol were significantly stronger in EOS than LOS (all p < 0.004). The differential distribution of stroke subtypes could not explain the difference in effect size observed between EOS and LOS. Conclusion These results suggest that interventions targeted at lowering body mass index and blood pressure may be particularly important for reducing stroke risk in young adults.
- Open Access
Exome Array Analysis of 9,721 ischemic stroke cases from the SiGN Consortium
Recent studies have identified > 40 genetic variants robustly associated with ischemic stroke, most identified through genome wide association studies and primarily marking common variants in non-coding regions presumed to have regulatory roles on gene and protein expression. To evaluate the contribution of coding variants, which are mostly rare, to the etiology of ischemic stroke, we performed an exome array analysis of 9,721 ischemic stroke cases with mean age of onset at 67.1 years from the SiGN Consortium, and 12,345 subjects with no history of stroke (mean age 67.0 years) from the Health Retirement Study and SiGN consortium. Both cohorts included people with diverse ancestries. Genotyping for both SiGN and HRS was performed using similar array content at the Center for Inherited Disease Research (CIDR), albeit as two separate studies. Following extensive SNP- and sample-level quality control, a total of 106,101 SNPs from the exome content was used for exome association analysis. We identified 15 coding variants significantly associated with all ischemic stroke at array-wide threshold for statistical significance (i.e., p < 3.6 × 10 −7 ) that also showed good genotyping quality, including two common SNPs in ABO that have previously been associated with stroke. Twelve of the remaining 13 variants were extremely rare in European Caucasians (MAFPRIM2 , rs199585353, was present exclusively in the stroke cases of European Caucasians while absent in all other samples from our data. There was no evidence for replication of these associations in either TOPMed Stroke samples (n = 5613 cases) or UK Biobank (n = 5,874 stroke cases), although power to replicate was very low given the low allele frequencies of the associated variants. In conclusion our analyses revealed 13 novel associations, but the low allele counts of associated variants and difficulty in acquiring large, well-powered replication highlight the challenges of rare variant association analysis, especially using array-based genotyping technologies.
Open AccessExome Array Analysis of 9,721 ischemic stroke cases from the SiGN Consortium
Recent studies have identified > 40 genetic variants robustly associated with ischemic stroke, most identified through genome wide association studies and primarily marking common variants in non-coding regions presumed to have regulatory roles on gene and protein expression. To evaluate the contribution of coding variants, which are mostly rare, to the etiology of ischemic stroke, we performed an exome array analysis of 9,721 ischemic stroke cases with mean age of onset at 67.1 years from the SiGN Consortium, and 12,345 subjects with no history of stroke (mean age 67.0 years) from the Health Retirement Study and SiGN consortium. Both cohorts included people with diverse ancestries. Genotyping for both SiGN and HRS was performed using similar array content at the Center for Inherited Disease Research (CIDR), albeit as two separate studies. Following extensive SNP- and sample-level quality control, a total of 106,101 SNPs from the exome content was used for exome association analysis. We identified 15 coding variants significantly associated with all ischemic stroke at array-wide threshold for statistical significance (i.e., p < 3.6 × 10 −7 ) that also showed good genotyping quality, including two common SNPs in ABO that have previously been associated with stroke. Twelve of the remaining 13 variants were extremely rare in European Caucasians (MAFPRIM2 , rs199585353, was present exclusively in the stroke cases of European Caucasians while absent in all other samples from our data. There was no evidence for replication of these associations in either TOPMed Stroke samples (n = 5613 cases) or UK Biobank (n = 5,874 stroke cases), although power to replicate was very low given the low allele frequencies of the associated variants. In conclusion our analyses revealed 13 novel associations, but the low allele counts of associated variants and difficulty in acquiring large, well-powered replication highlight the challenges of rare variant association analysis, especially using array-based genotyping technologies.
- Open Access
- 18 October 2022
- Published by Wolters Kluwer Health in Neurology
- Vol. 99 (16) , e1738-e1754
Contribution of Common Genetic Variants to Risk of Early-Onset Ischemic Stroke
Background and Objectives Current genome-wide association studies of ischemic stroke have focused primarily on late-onset disease. As a complement to these studies, we sought to identify the contribution of common genetic variants to risk of early-onset ischemic stroke. Methods We performed a meta-analysis of genome-wide association studies of early-onset stroke (EOS), ages 18–59 years, using individual-level data or summary statistics in 16,730 cases and 599,237 nonstroke controls obtained across 48 different studies. We further compared effect sizes at associated loci between EOS and late-onset stroke (LOS) and compared polygenic risk scores (PRS) for venous thromboembolism (VTE) between EOS and LOS. Results We observed genome-wide significant associations of EOS with 2 variants in ABO, a known stroke locus. These variants tag blood subgroups O1 and A1, and the effect sizes of both variants were significantly larger in EOS compared with LOS. The odds ratio (OR) for rs529565, tagging O1, was 0.88 (95% confidence interval [CI]: 0.85–0.91) in EOS vs 0.96 (95% CI: 0.92–1.00) in LOS, and the OR for rs635634, tagging A1, was 1.16 (1.11–1.21) for EOS vs 1.05 (0.99–1.11) in LOS; p-values for interaction = 0.001 and 0.005, respectively. Using PRSs, we observed that greater genetic risk for VTE, another prothrombotic condition, was more strongly associated with EOS compared with LOS (p = 0.008). Discussion The ABO locus, genetically predicted blood group A, and higher genetic propensity for venous thrombosis are more strongly associated with EOS than with LOS, supporting a stronger role of prothrombotic factors in EOS.
- 18 October 2022
- Published by Wolters Kluwer Health in Neurology
- Vol. 99 (16) , e1738-e1754
Open AccessContribution of Common Genetic Variants to Risk of Early-Onset Ischemic Stroke
Background and Objectives Current genome-wide association studies of ischemic stroke have focused primarily on late-onset disease. As a complement to these studies, we sought to identify the contribution of common genetic variants to risk of early-onset ischemic stroke. Methods We performed a meta-analysis of genome-wide association studies of early-onset stroke (EOS), ages 18–59 years, using individual-level data or summary statistics in 16,730 cases and 599,237 nonstroke controls obtained across 48 different studies. We further compared effect sizes at associated loci between EOS and late-onset stroke (LOS) and compared polygenic risk scores (PRS) for venous thromboembolism (VTE) between EOS and LOS. Results We observed genome-wide significant associations of EOS with 2 variants in ABO, a known stroke locus. These variants tag blood subgroups O1 and A1, and the effect sizes of both variants were significantly larger in EOS compared with LOS. The odds ratio (OR) for rs529565, tagging O1, was 0.88 (95% confidence interval [CI]: 0.85–0.91) in EOS vs 0.96 (95% CI: 0.92–1.00) in LOS, and the OR for rs635634, tagging A1, was 1.16 (1.11–1.21) for EOS vs 1.05 (0.99–1.11) in LOS; p-values for interaction = 0.001 and 0.005, respectively. Using PRSs, we observed that greater genetic risk for VTE, another prothrombotic condition, was more strongly associated with EOS compared with LOS (p = 0.008). Discussion The ABO locus, genetically predicted blood group A, and higher genetic propensity for venous thrombosis are more strongly associated with EOS than with LOS, supporting a stronger role of prothrombotic factors in EOS.
- Open Access
- 15 June 2021
- Published by Springer Nature in Nature Communications
- Vol. 12 (1) , 1-13
Genome sequencing unveils a regulatory landscape of platelet reactivity
Platelet aggregation at the site of atherosclerotic vascular injury is the underlying pathophysiology of myocardial infarction and stroke. To build upon prior GWAS, here we report on 16 loci identified through a whole genome sequencing (WGS) approach in 3,855 NHLBI Trans-Omics for Precision Medicine (TOPMed) participants deeply phenotyped for platelet aggregation. We identify the RGS18 locus, which encodes a myeloerythroid lineage-specific regulator of G-protein signaling that co-localizes with expression quantitative trait loci (eQTL) signatures for RGS18 expression in platelets. Gene-based approaches implicate the SVEP1 gene, a known contributor of coronary artery disease risk. Sentinel variants at RGS18 and PEAR1 are associated with thrombosis risk and increased gastrointestinal bleeding risk, respectively. Our WGS findings add to previously identified GWAS loci, provide insights regarding the mechanism(s) by which genetics may influence cardiovascular disease risk, and underscore the importance of rare variant and regulatory approaches to identifying loci contributing to complex phenotypes.
- 15 June 2021
- Published by Springer Nature in Nature Communications
- Vol. 12 (1) , 1-13
Open AccessGenome sequencing unveils a regulatory landscape of platelet reactivity
Platelet aggregation at the site of atherosclerotic vascular injury is the underlying pathophysiology of myocardial infarction and stroke. To build upon prior GWAS, here we report on 16 loci identified through a whole genome sequencing (WGS) approach in 3,855 NHLBI Trans-Omics for Precision Medicine (TOPMed) participants deeply phenotyped for platelet aggregation. We identify the RGS18 locus, which encodes a myeloerythroid lineage-specific regulator of G-protein signaling that co-localizes with expression quantitative trait loci (eQTL) signatures for RGS18 expression in platelets. Gene-based approaches implicate the SVEP1 gene, a known contributor of coronary artery disease risk. Sentinel variants at RGS18 and PEAR1 are associated with thrombosis risk and increased gastrointestinal bleeding risk, respectively. Our WGS findings add to previously identified GWAS loci, provide insights regarding the mechanism(s) by which genetics may influence cardiovascular disease risk, and underscore the importance of rare variant and regulatory approaches to identifying loci contributing to complex phenotypes.
- Open Access
An Omics Analysis Search and Information System (OASIS) for Enabling Biological Discovery in the Old Order Amish
The “Omics Analysis Search and Information System” (OASIS), developed at the University of Maryland School of Medicine, enables discovery by allowing researchers to mine results from genome wide association studies (GWAS). When interesting signals are found, the research can immediately ask follow-up questions and get answers in real-time. OASIS provides this unique capability with a web-based, scientist-friendly search system and a variety of real-time analysis tools (linkage disequilibrium calculations, conditional analysis, and direct variant comparison) plus on-demand visualizations (boxplots, histograms, LocusZoom & Haploview plots, and pedigree charts). Because OASIS uses a web-based user interface, an understanding of programming or the UNIX operating system is not required. The OASIS application has been used to enable discovery from whole-exome, whole-genome, metabolome, transcriptome and methylome association results for Old Order Amish studies at the University of Maryland School of Medicine.
Open AccessAn Omics Analysis Search and Information System (OASIS) for Enabling Biological Discovery in the Old Order Amish
The “Omics Analysis Search and Information System” (OASIS), developed at the University of Maryland School of Medicine, enables discovery by allowing researchers to mine results from genome wide association studies (GWAS). When interesting signals are found, the research can immediately ask follow-up questions and get answers in real-time. OASIS provides this unique capability with a web-based, scientist-friendly search system and a variety of real-time analysis tools (linkage disequilibrium calculations, conditional analysis, and direct variant comparison) plus on-demand visualizations (boxplots, histograms, LocusZoom & Haploview plots, and pedigree charts). Because OASIS uses a web-based user interface, an understanding of programming or the UNIX operating system is not required. The OASIS application has been used to enable discovery from whole-exome, whole-genome, metabolome, transcriptome and methylome association results for Old Order Amish studies at the University of Maryland School of Medicine.
- Open Access
- 19 April 2021
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 16 (4) , e0248791
The copy number variation and stroke (CaNVAS) risk and outcome study
Background and purpose: The role of copy number variation (CNV) variation in stroke susceptibility and outcome has yet to be explored. The Copy Number Variation and Stroke (CaNVAS) Risk and Outcome study addresses this knowledge gap. Methods: Over 24,500 well-phenotyped IS cases, including IS subtypes, and over 43,500 controls have been identified, all with readily available genotyping on GWAS and exome arrays, with case measures of stroke outcome. To evaluate CNV-associated stroke risk and stroke outcome it is planned to: 1) perform Risk Discovery using several analytic approaches to identify CNVs that are associated with the risk of IS and its subtypes, across the age-, sex- and ethnicity-spectrums; 2) perform Risk Replication and Extension to determine whether the identified stroke-associated CNVs replicate in other ethnically diverse datasets and use biomarker data (e.g. methylation, proteomic, RNA, miRNA, etc.) to evaluate how the identified CNVs exert their effects on stroke risk, and lastly; 3) perform outcome-based Replication and Extension analyses of recent findings demonstrating an inverse relationship between CNV burden and stroke outcome at 3 months (mRS), and then determine the key CNV drivers responsible for these associations using existing biomarker data. Results: The results of an initial CNV evaluation of 50 samples from each participating dataset are presented demonstrating that the existing GWAS and exome chip data are excellent for the planned CNV analyses. Further, some samples will require additional considerations for analysis, however such samples can readily be identified, as demonstrated by a sample demonstrating clonal mosaicism. Conclusion: The CaNVAS study will cost-effectively leverage the numerous advantages of using existing case-control data sets, exploring the relationships between CNV and IS and its subtypes, and outcome at 3 months, in both men and women, in those of African and European-Caucasian descent, this, across the entire adult-age spectrum.
- 19 April 2021
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 16 (4) , e0248791
Open AccessThe copy number variation and stroke (CaNVAS) risk and outcome study
Background and purpose: The role of copy number variation (CNV) variation in stroke susceptibility and outcome has yet to be explored. The Copy Number Variation and Stroke (CaNVAS) Risk and Outcome study addresses this knowledge gap. Methods: Over 24,500 well-phenotyped IS cases, including IS subtypes, and over 43,500 controls have been identified, all with readily available genotyping on GWAS and exome arrays, with case measures of stroke outcome. To evaluate CNV-associated stroke risk and stroke outcome it is planned to: 1) perform Risk Discovery using several analytic approaches to identify CNVs that are associated with the risk of IS and its subtypes, across the age-, sex- and ethnicity-spectrums; 2) perform Risk Replication and Extension to determine whether the identified stroke-associated CNVs replicate in other ethnically diverse datasets and use biomarker data (e.g. methylation, proteomic, RNA, miRNA, etc.) to evaluate how the identified CNVs exert their effects on stroke risk, and lastly; 3) perform outcome-based Replication and Extension analyses of recent findings demonstrating an inverse relationship between CNV burden and stroke outcome at 3 months (mRS), and then determine the key CNV drivers responsible for these associations using existing biomarker data. Results: The results of an initial CNV evaluation of 50 samples from each participating dataset are presented demonstrating that the existing GWAS and exome chip data are excellent for the planned CNV analyses. Further, some samples will require additional considerations for analysis, however such samples can readily be identified, as demonstrated by a sample demonstrating clonal mosaicism. Conclusion: The CaNVAS study will cost-effectively leverage the numerous advantages of using existing case-control data sets, exploring the relationships between CNV and IS and its subtypes, and outcome at 3 months, in both men and women, in those of African and European-Caucasian descent, this, across the entire adult-age spectrum.